CRC Research Update — September 07, 2026
Today's colorectal cancer research highlights
Archive
A collection of 699 issues
Latest
Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC
Skip to content
The CRC Digest
Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC
A retrospective study of 145 patients with microsatellite-stable metastatic CRC who had progressed after at least two systemic treatment lines aimed to evaluate whether fruquintinib alone, fruquintinib plus a PD-1 inhibitor, or the combination with radiotherapy
Hospitalization outcomes differ between early- and late-onset CRC patients
Skip to content
The CRC Digest
Hospitalization outcomes differ between early- and late-onset CRC patients
A national database study (2016-2020) compared hospitalization trends and outcomes in patients diagnosed before age 50 versus those 50 and older, finding distinct patterns in mortality, length of stay, and associations with obesity and sociodemographic
Dietary and metabolic risk factors drive rising early-onset CRC rates in the U.S.
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Dietary and metabolic risk factors drive rising early-onset CRC rates in the U.S.
A 33-year analysis of Global Burden of Disease data shows that while traditional colorectal cancer rates in older adults have declined, early-onset cases (diagnosed under age 50)
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy
Skip to content
The CRC Digest
◇ RESEARCH
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy
A systematic review of patients with tissue RAS wild-type tumors receiving first-line chemotherapy plus anti-EGFR therapy found inconsistent results on whether ctDNA RAS status predicts outcomes, possibly due to differences in assay
Tracking ctDNA after surgery identifies high-risk patients despite negative MRD status
Skip to content
The CRC Digest
◇ RESEARCH
Tracking ctDNA after surgery identifies high-risk patients despite negative MRD status
A longitudinal study of 124 stage II-III patients found that analyzing circulating tumor DNA (ctDNA) trajectories after surgery can identify subgroups at high risk for recurrence or metastasis, even when initial minimal
COMMIT trial analysis examines chemoimmunotherapy in dMMR metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
COMMIT trial analysis examines chemoimmunotherapy in dMMR metastatic CRC
A new analysis explores what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology)
This
CRC Research Update — September 06, 2026
Today's colorectal cancer research highlights
Blood-based screening may reduce barriers for adults with intellectual disabilities
Skip to content
The CRC Digest
▪ SCREENING
Blood-based screening may reduce barriers for adults with intellectual disabilities
Adults with intellectual and developmental disabilities face substantial barriers to CRC screening, and blood-based tests may reduce logistical barriers, though current Medicaid coverage gaps limit accessibility for this population. (Cureus)
This content is
CRC burden rising fastest in adults under 50
Skip to content
The CRC Digest
▪ SCREENING
CRC burden rising fastest in adults under 50
Analysis of GBD 2023 data found CRC incidence rose most in adults aged 15-44 (+16.8%). (Annals of Medicine)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or